News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celator Pharmaceuticals, Inc. Receives U.S. Patent on Proprietary Liposome Composition


8/30/2013 9:41:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EWING, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that U.S. Patent number 8,518,437 was issued by the United States Patent and Trademark Office on August 27, 2013. The new patent, “Lipid Carrier Compositions with Enhanced Blood Stability,” covers Celator’s proprietary low-cholesterol liposome compositions utilized in the Company's two clinical stage products, CPX-351 and CPX-1, which are based on the company’s innovative technology platform called CombiPlex. With the Patent Term Adjustment, this patent provides protection until June 2026.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES